The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2017 | What can clonal evolution in chronic lymphocytic leukemia (CLL) tell us about outcomes?
Elias Campo, MD, PhD, from the University of Barcelona, Hospital Clinic, Barcelona, Spain, discusses clonal evolution in chronic lymphocytic leukemia (CLL) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He explains that while some tumors are homogenous, others have a great degree of heterogeneity. Dr Campo speaks about how different subclones display different mutations. According to Dr Campo, recent data indicate that homogenous tumors are associated with better outcomes. He also highlights the value of collaboration in understanding the complex biology of clonal evolution.
